论文部分内容阅读
目的 研究骨肉瘤中TopoⅠ的表达情况,探讨其与TopoⅡ、Ki67之间的相互关系和临床意义。方法 采用S-P免疫组化方法,检测TopoⅠ、TopoⅡ和Ki67在67例骨肉瘤、10例骨样骨瘤、15骨软骨瘤及15例正常骨组织中的表达,分析相互间的关系,对其中31例随访资料进行生存分析。结果 67例骨肉瘤中,TopoⅠ、TopoⅡ与和Ki67的表达率分别为22.39％、44.78％和40.30％,均明显增高,同患者术后生存率呈负相关;TopoⅠ、TopoⅡ的表达率与应用于临床的抗DNA拓扑异构酶化疗药物有效率相近。结论骨肉瘤中有小部分患者对于新的以TopoⅠ为靶点的化疗药物敏感,对骨肉瘤组织行免疫组化方法检测TopoⅠ、TopoⅡ可能作为骨肉瘤患者选择化疗方案一个较为简单又有意义的指标。
Objective To study the expression of Topo Ⅰ in osteosarcoma and to explore its relationship with Topo Ⅱ and Ki67 and its clinical significance. Methods The expression of TopoⅠ, TopoⅡ and Ki67 in 67 cases of osteosarcoma, 10 cases of osteoid osteoma, 15 cases of osteochondrosis and 15 cases of normal bone tissue were detected by SP immunohistochemistry. The relationship between them was analyzed. Follow-up data were analyzed for survival. Results The expression rates of TopoⅠ, TopoⅡ and Ki67 in osteosarcoma of 67 cases were 22.39%, 44.78% and 40.30%, respectively, which were significantly higher than those of the other two groups Clinical anti-DNA topoisomerase chemotherapeutic drugs have similar efficacies. Conclusions A small number of patients with osteosarcoma are sensitive to new chemotherapeutic drugs targeting Topo I. The detection of Topo I and Topo II by immunohistochemistry in osteosarcoma tissue may be a simple and meaningful indicator for selecting chemotherapy regimen for patients with osteosarcoma .